• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Howe Jill Ann was granted 12,500 shares, increasing direct ownership by 64% to 31,916 units (SEC Form 4)

    6/6/24 4:33:47 PM ET
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIOR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Howe Jill Ann

    (Last) (First) (Middle)
    C/O BIORA THERAPEUTICS, INC.
    4330 LA JOLLA VILLAGE DRIVE, SUITE 300

    (Street)
    SAN DIEGO CA 92122

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BIORA THERAPEUTICS, INC. [ BIOR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/05/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/05/2024 A 12,500(1) A $0 31,916 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $0.7 06/05/2024 A 12,500 (2) 06/05/2034 Common Stock 12,500 $0 12,500 D
    Explanation of Responses:
    1. Represents 12,500 restricted stock units, which vest in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.
    2. This option represents the right to purchase 12,500 shares of the Issuer's common stock, and vests in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.
    /s/ Clarke Neumann, Attorney-in-Fact for Jill Ann Howe 06/06/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BIOR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIOR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Athyrium Opportunities Iii Co-Invest 1 Lp

    4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)

    12/16/24 7:32:19 PM ET
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Neumann Clarke covered exercise/tax liability with 26,629 shares, decreasing direct ownership by 5% to 465,564 units (SEC Form 4)

    4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)

    8/16/24 4:05:05 PM ET
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Desparbes Eric covered exercise/tax liability with 27,830 shares, decreasing direct ownership by 5% to 575,832 units (SEC Form 4)

    4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)

    8/16/24 4:05:04 PM ET
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biora Therapeutics Successfully Completes Restructuring Process

    SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Biora Therapeutics, a biotech company developing the first swallowable autoinjector, today announced the successful completion of its court-supervised restructuring. Through the restructuring process, Biora achieved an improved balance sheet with deleveraged debt and significant new financing to support the business going forward. Biora has emerged from the restructuring as a privately held company. "Emergence marks a new beginning for us as a leaner, stronger, well-capitalized company with a mission to revolutionize the way biologic pharmaceuticals are delivered to patients," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "W

    3/31/25 8:00:00 AM ET
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth

    Sale process will help enable next stage of product development Secures up to $10.25 million in new financing to support ongoing business operations SAN DIEGO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. ("Biora" or the "Company"), a biotech company developing smart pill-based therapeutic platforms, today announced it has reached an agreement with certain of its prepetition creditors (the "Lenders") to provide financing to support a chapter 11 sale process, which will ultimately lead to a strengthened balance sheet and help enable it to launch its next stage of product development. To effectuate the transaction, the Company has filed a voluntary petition under chapter 11 o

    12/30/24 8:00:00 AM ET
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

    Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable Company granted extension until December 9 to regain compliance with Nasdaq listing requirements for market value of securities SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. The company will not host a conference call. "We've made much faster progress than anticipated developing a smaller BioJet device that is highly desired by pharma companies," said A

    11/14/24 8:00:00 AM ET
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOR
    SEC Filings

    View All

    Biora Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)

    12/30/24 8:07:03 AM ET
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Biora Therapeutics Inc.

    8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)

    12/10/24 7:00:07 AM ET
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Biora Therapeutics Inc.

    8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)

    11/15/24 4:05:09 PM ET
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOR
    Financials

    Live finance-specific insights

    View All

    Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

    Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable Company granted extension until December 9 to regain compliance with Nasdaq listing requirements for market value of securities SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. The company will not host a conference call. "We've made much faster progress than anticipated developing a smaller BioJet device that is highly desired by pharma companies," said A

    11/14/24 8:00:00 AM ET
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update

    SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2024. Company management will host a webcast and conference call on Thursday, November 14, 2024, after the close of financial markets. Conference Call and Webcast InformationDate: Thursday, November 14, 2024Time: 4:30 PM Eastern time / 1:30 PM Pacific timeConference Call: Domestic 1-877-423-9813International 1-201-689-8573Conference ID 13749254Live Webcast: https://investors.bioratherapeutics.com/events-presentations A replay will

    11/7/24 4:30:00 PM ET
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

    Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan Company secures up to $16M funding from existing investors supported by BT-600 results and progress toward BioJet™ partnership Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the second quarter ended June 30, 2024. "Research shows that ulcerative colitis patients with higher drug exposur

    8/12/24 4:15:00 PM ET
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOR
    Leadership Updates

    Live Leadership Updates

    View All

    Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer

    SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced the appointment of Ariella Kelman, MD, as Chief Medical Officer. Dr. Kelman has a proven track record of leading global biopharmaceutical development, clinical trials, and regulatory strategies. "Dr. Kelman is an outstanding addition to our team as we progress our programs into later stages of development and prepare to enter the clinic with the BT-600 program, which is designed to deliver our unique formulation of tofacitinib to the colon using our proprietary GItrac™ technology," said Adi Mohanty, Chief Executive Officer of Bio

    5/1/23 9:00:00 AM ET
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biora Therapeutics Appoints Dr. Bruce Sands as Chair of its Clinical Advisory Board

    SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutics, announced today the appointment of Dr. Bruce Sands as board chair of its Clinical Advisory Board for Inflammatory Bowel Disease (IBD), which also includes leading IBD researchers Dr. Geert D'Haens, Dr. Brian Feagan, and Dr. Séverine Vermeire. The clinical advisory board provides strategic guidance on clinical development of Biora's Targeted Therapeutics pipeline. "Targeted drug delivery to the large intestine has the potential to enable new therapeutic approaches, including combination therapy, for IBD patients," said Dr. Bruce Sands. "I'm pleased to

    9/7/22 9:00:00 AM ET
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Biora Therapeutics Inc.

    SC 13G - BIORA THERAPEUTICS, INC. (0001580063) (Subject)

    11/14/24 10:01:30 AM ET
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Biora Therapeutics Inc.

    SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)

    10/9/24 5:40:25 PM ET
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Biora Therapeutics Inc.

    SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)

    9/13/24 10:37:57 AM ET
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care